SB 505124

Key Product Details

Product Description

SB 505124 is a selective inhibitor of transforming growth factor-β type I receptor (ALK5), ALK4 and ALK7 (IC₅₀ values are 47 and 129 nM for ALK5 and ALK4 respectively). Selectively inhibits signaling from TGF-β and activin; does not inhibit other ALK family members. Promotes adenine base editor activity in vivo and in vitro at 10 μM.

Product Specifications for SB 505124

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for SB 505124

The following data is based on the product molecular weight 335.40.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.98 mL	14.91 mL	29.82 mL
5 mM	0.60 mL	2.98 mL	5.96 mL
10 mM	0.30 mL	1.49 mL	2.98 mL
50 mM	0.06 mL	0.30 mL	0.60 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 55 publications citing the usage of this product.

• Yang Small-molecule activators specific to adenine base editors through blocking the canonical TGF-β pathway. Nucleic Acids Res. 2022 PMID: 36043443
• Hu Reactive oxygen species production via NADPH oxidase mediates TGF-β-induced cytoskeletal alterations in endothelial cells. Am.J.Physiol.Renal Physiol. 2005 PMID: 16159901
• Noma The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology 2008 PMID: 18439605
• Byfield SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol.Pharmacol. 2004 PMID: 14978253

Product Documents for SB 505124